Home > > > > > Report Detail

Global Hepatocellular Carcinoma Drugs Market Size, Status and Forecast 2021-2027

Publisher Name :
Date: 13-Jul-2021
No. of pages: 105
Inquire Before Buying

HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.

The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2017. The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury. The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market. However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.

Market Analysis and Insights: Global Hepatocellular Carcinoma Drugs Market

The global Hepatocellular Carcinoma Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hepatocellular Carcinoma Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hepatocellular Carcinoma Drugs market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hepatocellular Carcinoma Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hepatocellular Carcinoma Drugs market.

Global Hepatocellular Carcinoma Drugs Scope and Market Size

Hepatocellular Carcinoma Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hepatocellular Carcinoma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type

- Brachytherapy

- Chemotherapy

- Local Ablation Therapy

Segment by Application

- Hospitals

- Clinics

- Cancer Rehabilitation Centers

By Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- - Nordic

- - Rest of Europe

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - Southeast Asia

- - India

- - Australia

- - Rest of Asia

- Latin America

- - Mexico

- - Brazil

- - Rest of Latin America

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

- - Rest of MEA

By Company

- Bayer

- Eli Lilly

- Johnson and Johnson

- Pfizer

- Bristol-Myers Squibb

- Celgene

- F. Hoffmann-la Roche

- Gilead

- GlaxoSmithKline

- Merck

- Novartis

Global Hepatocellular Carcinoma Drugs Market Size, Status and Forecast 2021-2027

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hepatocellular Carcinoma Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Brachytherapy
1.2.3 Chemotherapy
1.2.4 Local Ablation Therapy
1.3 Market by Application
1.3.1 Global Hepatocellular Carcinoma Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Cancer Rehabilitation Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Hepatocellular Carcinoma Drugs Market Perspective (2016-2027)
2.2 Hepatocellular Carcinoma Drugs Growth Trends by Regions
2.2.1 Hepatocellular Carcinoma Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Hepatocellular Carcinoma Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Hepatocellular Carcinoma Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Hepatocellular Carcinoma Drugs Industry Dynamic
2.3.1 Hepatocellular Carcinoma Drugs Market Trends
2.3.2 Hepatocellular Carcinoma Drugs Market Drivers
2.3.3 Hepatocellular Carcinoma Drugs Market Challenges
2.3.4 Hepatocellular Carcinoma Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hepatocellular Carcinoma Drugs Players by Revenue
3.1.1 Global Top Hepatocellular Carcinoma Drugs Players by Revenue (2016-2021)
3.1.2 Global Hepatocellular Carcinoma Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Hepatocellular Carcinoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Hepatocellular Carcinoma Drugs Revenue
3.4 Global Hepatocellular Carcinoma Drugs Market Concentration Ratio
3.4.1 Global Hepatocellular Carcinoma Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hepatocellular Carcinoma Drugs Revenue in 2020
3.5 Hepatocellular Carcinoma Drugs Key Players Head office and Area Served
3.6 Key Players Hepatocellular Carcinoma Drugs Product Solution and Service
3.7 Date of Enter into Hepatocellular Carcinoma Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hepatocellular Carcinoma Drugs Breakdown Data by Type
4.1 Global Hepatocellular Carcinoma Drugs Historic Market Size by Type (2016-2021)
4.2 Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Type (2022-2027)
5 Hepatocellular Carcinoma Drugs Breakdown Data by Application
5.1 Global Hepatocellular Carcinoma Drugs Historic Market Size by Application (2016-2021)
5.2 Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Hepatocellular Carcinoma Drugs Market Size (2016-2027)
6.2 North America Hepatocellular Carcinoma Drugs Market Size by Type
6.2.1 North America Hepatocellular Carcinoma Drugs Market Size by Type (2016-2021)
6.2.2 North America Hepatocellular Carcinoma Drugs Market Size by Type (2022-2027)
6.2.3 North America Hepatocellular Carcinoma Drugs Market Size by Type (2016-2027)
6.3 North America Hepatocellular Carcinoma Drugs Market Size by Application
6.3.1 North America Hepatocellular Carcinoma Drugs Market Size by Application (2016-2021)
6.3.2 North America Hepatocellular Carcinoma Drugs Market Size by Application (2022-2027)
6.3.3 North America Hepatocellular Carcinoma Drugs Market Size by Application (2016-2027)
6.4 North America Hepatocellular Carcinoma Drugs Market Size by Country
6.4.1 North America Hepatocellular Carcinoma Drugs Market Size by Country (2016-2021)
6.4.2 North America Hepatocellular Carcinoma Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Hepatocellular Carcinoma Drugs Market Size (2016-2027)
7.2 Europe Hepatocellular Carcinoma Drugs Market Size by Type
7.2.1 Europe Hepatocellular Carcinoma Drugs Market Size by Type (2016-2021)
7.2.2 Europe Hepatocellular Carcinoma Drugs Market Size by Type (2022-2027)
7.2.3 Europe Hepatocellular Carcinoma Drugs Market Size by Type (2016-2027)
7.3 Europe Hepatocellular Carcinoma Drugs Market Size by Application
7.3.1 Europe Hepatocellular Carcinoma Drugs Market Size by Application (2016-2021)
7.3.2 Europe Hepatocellular Carcinoma Drugs Market Size by Application (2022-2027)
7.3.3 Europe Hepatocellular Carcinoma Drugs Market Size by Application (2016-2027)
7.4 Europe Hepatocellular Carcinoma Drugs Market Size by Country
7.4.1 Europe Hepatocellular Carcinoma Drugs Market Size by Country (2016-2021)
7.4.2 Europe Hepatocellular Carcinoma Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size (2016-2027)
8.2 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Type
8.2.1 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Application
8.3.1 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Region
8.4.1 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Hepatocellular Carcinoma Drugs Market Size (2016-2027)
9.2 Latin America Hepatocellular Carcinoma Drugs Market Size by Type
9.2.1 Latin America Hepatocellular Carcinoma Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Hepatocellular Carcinoma Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Hepatocellular Carcinoma Drugs Market Size by Type (2016-2027)
9.3 Latin America Hepatocellular Carcinoma Drugs Market Size by Application
9.3.1 Latin America Hepatocellular Carcinoma Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Hepatocellular Carcinoma Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Hepatocellular Carcinoma Drugs Market Size by Application (2016-2027)
9.4 Latin America Hepatocellular Carcinoma Drugs Market Size by Country
9.4.1 Latin America Hepatocellular Carcinoma Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Hepatocellular Carcinoma Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size (2016-2027)
10.2 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Type
10.2.1 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Application
10.3.1 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Country
10.4.1 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Details
11.1.2 Bayer Business Overview
11.1.3 Bayer Hepatocellular Carcinoma Drugs Introduction
11.1.4 Bayer Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021)
11.1.5 Bayer Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Hepatocellular Carcinoma Drugs Introduction
11.2.4 Eli Lilly Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021)
11.2.5 Eli Lilly Recent Development
11.3 Johnson and Johnson
11.3.1 Johnson and Johnson Company Details
11.3.2 Johnson and Johnson Business Overview
11.3.3 Johnson and Johnson Hepatocellular Carcinoma Drugs Introduction
11.3.4 Johnson and Johnson Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021)
11.3.5 Johnson and Johnson Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Hepatocellular Carcinoma Drugs Introduction
11.4.4 Pfizer Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Details
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Introduction
11.5.4 Bristol-Myers Squibb Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Celgene
11.6.1 Celgene Company Details
11.6.2 Celgene Business Overview
11.6.3 Celgene Hepatocellular Carcinoma Drugs Introduction
11.6.4 Celgene Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021)
11.6.5 Celgene Recent Development
11.7 F. Hoffmann-la Roche
11.7.1 F. Hoffmann-la Roche Company Details
11.7.2 F. Hoffmann-la Roche Business Overview
11.7.3 F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Introduction
11.7.4 F. Hoffmann-la Roche Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021)
11.7.5 F. Hoffmann-la Roche Recent Development
11.8 Gilead
11.8.1 Gilead Company Details
11.8.2 Gilead Business Overview
11.8.3 Gilead Hepatocellular Carcinoma Drugs Introduction
11.8.4 Gilead Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021)
11.8.5 Gilead Recent Development
11.9 GlaxoSmithKline
11.9.1 GlaxoSmithKline Company Details
11.9.2 GlaxoSmithKline Business Overview
11.9.3 GlaxoSmithKline Hepatocellular Carcinoma Drugs Introduction
11.9.4 GlaxoSmithKline Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021)
11.9.5 GlaxoSmithKline Recent Development
11.10 Merck
11.10.1 Merck Company Details
11.10.2 Merck Business Overview
11.10.3 Merck Hepatocellular Carcinoma Drugs Introduction
11.10.4 Merck Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021)
11.10.5 Merck Recent Development
11.11 Novartis
11.11.1 Novartis Company Details
11.11.2 Novartis Business Overview
11.11.3 Novartis Hepatocellular Carcinoma Drugs Introduction
11.11.4 Novartis Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021)
11.11.5 Novartis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Hepatocellular Carcinoma Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Brachytherapy
Table 3. Key Players of Chemotherapy
Table 4. Key Players of Local Ablation Therapy
Table 5. Global Hepatocellular Carcinoma Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Hepatocellular Carcinoma Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Hepatocellular Carcinoma Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Hepatocellular Carcinoma Drugs Market Share by Regions (2016-2021)
Table 9. Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Hepatocellular Carcinoma Drugs Market Share by Regions (2022-2027)
Table 11. Hepatocellular Carcinoma Drugs Market Trends
Table 12. Hepatocellular Carcinoma Drugs Market Drivers
Table 13. Hepatocellular Carcinoma Drugs Market Challenges
Table 14. Hepatocellular Carcinoma Drugs Market Restraints
Table 15. Global Hepatocellular Carcinoma Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Hepatocellular Carcinoma Drugs Market Share by Players (2016-2021)
Table 17. Global Top Hepatocellular Carcinoma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatocellular Carcinoma Drugs as of 2020)
Table 18. Ranking of Global Top Hepatocellular Carcinoma Drugs Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Hepatocellular Carcinoma Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Hepatocellular Carcinoma Drugs Product Solution and Service
Table 22. Date of Enter into Hepatocellular Carcinoma Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Hepatocellular Carcinoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Hepatocellular Carcinoma Drugs Revenue Market Share by Type (2016-2021)
Table 26. Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Hepatocellular Carcinoma Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Hepatocellular Carcinoma Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Hepatocellular Carcinoma Drugs Revenue Market Share by Application (2016-2021)
Table 30. Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Hepatocellular Carcinoma Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Hepatocellular Carcinoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Hepatocellular Carcinoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Hepatocellular Carcinoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Hepatocellular Carcinoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Hepatocellular Carcinoma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Hepatocellular Carcinoma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Hepatocellular Carcinoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Hepatocellular Carcinoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Hepatocellular Carcinoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Hepatocellular Carcinoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Hepatocellular Carcinoma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Hepatocellular Carcinoma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Hepatocellular Carcinoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Hepatocellular Carcinoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Hepatocellular Carcinoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Hepatocellular Carcinoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Hepatocellular Carcinoma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Hepatocellular Carcinoma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 62. Bayer Company Details
Table 63. Bayer Business Overview
Table 64. Bayer Hepatocellular Carcinoma Drugs Product
Table 65. Bayer Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 66. Bayer Recent Development
Table 67. Eli Lilly Company Details
Table 68. Eli Lilly Business Overview
Table 69. Eli Lilly Hepatocellular Carcinoma Drugs Product
Table 70. Eli Lilly Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 71. Eli Lilly Recent Development
Table 72. Johnson and Johnson Company Details
Table 73. Johnson and Johnson Business Overview
Table 74. Johnson and Johnson Hepatocellular Carcinoma Drugs Product
Table 75. Johnson and Johnson Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 76. Johnson and Johnson Recent Development
Table 77. Pfizer Company Details
Table 78. Pfizer Business Overview
Table 79. Pfizer Hepatocellular Carcinoma Drugs Product
Table 80. Pfizer Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 81. Pfizer Recent Development
Table 82. Bristol-Myers Squibb Company Details
Table 83. Bristol-Myers Squibb Business Overview
Table 84. Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Product
Table 85. Bristol-Myers Squibb Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 86. Bristol-Myers Squibb Recent Development
Table 87. Celgene Company Details
Table 88. Celgene Business Overview
Table 89. Celgene Hepatocellular Carcinoma Drugs Product
Table 90. Celgene Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 91. Celgene Recent Development
Table 92. F. Hoffmann-la Roche Company Details
Table 93. F. Hoffmann-la Roche Business Overview
Table 94. F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Product
Table 95. F. Hoffmann-la Roche Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 96. F. Hoffmann-la Roche Recent Development
Table 97. Gilead Company Details
Table 98. Gilead Business Overview
Table 99. Gilead Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 100. Gilead Recent Development
Table 101. GlaxoSmithKline Company Details
Table 102. GlaxoSmithKline Business Overview
Table 103. GlaxoSmithKline Hepatocellular Carcinoma Drugs Product
Table 104. GlaxoSmithKline Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 105. GlaxoSmithKline Recent Development
Table 106. Merck Company Details
Table 107. Merck Business Overview
Table 108. Merck Hepatocellular Carcinoma Drugs Product
Table 109. Merck Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 110. Merck Recent Development
Table 111. Novartis Company Details
Table 112. Novartis Business Overview
Table 113. Novartis Hepatocellular Carcinoma Drugs Product
Table 114. Novartis Revenue in Hepatocellular Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 115. Novartis Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hepatocellular Carcinoma Drugs Market Share by Type: 2020 VS 2027
Figure 2. Brachytherapy Features
Figure 3. Chemotherapy Features
Figure 4. Local Ablation Therapy Features
Figure 5. Global Hepatocellular Carcinoma Drugs Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Cancer Rehabilitation Centers Case Studies
Figure 9. Hepatocellular Carcinoma Drugs Report Years Considered
Figure 10. Global Hepatocellular Carcinoma Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Hepatocellular Carcinoma Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Hepatocellular Carcinoma Drugs Market Share by Regions: 2020 VS 2027
Figure 13. Global Hepatocellular Carcinoma Drugs Market Share by Regions (2022-2027)
Figure 14. Global Hepatocellular Carcinoma Drugs Market Share by Players in 2020
Figure 15. Global Top Hepatocellular Carcinoma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatocellular Carcinoma Drugs as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Hepatocellular Carcinoma Drugs Revenue in 2020
Figure 17. Global Hepatocellular Carcinoma Drugs Revenue Market Share by Type (2016-2021)
Figure 18. Global Hepatocellular Carcinoma Drugs Revenue Market Share by Type (2022-2027)
Figure 19. North America Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Hepatocellular Carcinoma Drugs Market Share by Type (2016-2027)
Figure 21. North America Hepatocellular Carcinoma Drugs Market Share by Application (2016-2027)
Figure 22. North America Hepatocellular Carcinoma Drugs Market Share by Country (2016-2027)
Figure 23. United States Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Hepatocellular Carcinoma Drugs Market Share by Type (2016-2027)
Figure 27. Europe Hepatocellular Carcinoma Drugs Market Share by Application (2016-2027)
Figure 28. Europe Hepatocellular Carcinoma Drugs Market Share by Country (2016-2027)
Figure 29. Germany Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Hepatocellular Carcinoma Drugs Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Hepatocellular Carcinoma Drugs Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Hepatocellular Carcinoma Drugs Market Share by Region (2016-2027)
Figure 39. China Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Hepatocellular Carcinoma Drugs Market Share by Type (2016-2027)
Figure 47. Latin America Hepatocellular Carcinoma Drugs Market Share by Application (2016-2027)
Figure 48. Latin America Hepatocellular Carcinoma Drugs Market Share by Country (2016-2027)
Figure 49. Mexico Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Hepatocellular Carcinoma Drugs Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Hepatocellular Carcinoma Drugs Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Hepatocellular Carcinoma Drugs Market Share by Country (2016-2027)
Figure 55. Turkey Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Hepatocellular Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Bayer Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2016-2021)
Figure 59. Eli Lilly Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2016-2021)
Figure 60. Johnson and Johnson Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2016-2021)
Figure 61. Pfizer Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2016-2021)
Figure 62. Bristol-Myers Squibb Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2016-2021)
Figure 63. Celgene Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2016-2021)
Figure 64. F. Hoffmann-la Roche Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2016-2021)
Figure 65. Gilead Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2016-2021)
Figure 66. GlaxoSmithKline Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2016-2021)
Figure 67. Merck Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2016-2021)
Figure 68. Novartis Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
  • Global 5-Fluorouracil Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 76
    The global 5-Fluorouracil market was valued at US$ 283 million in 2023 and is anticipated to reach US$ 487.9 million by 2030, witnessing a CAGR of 4.3% during The forecast period 2024-2030. North American market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by ......
  • Global Carboplatin Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79
    The global Carboplatin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % d......
  • Global Neutropenia Drugs Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 96
    The global Neutropenia Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated to increa......
  • Global Small Molecule Cancer Drug Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Small Molecule Cancer Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated ......
  • Global Capecitabine Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 80
    Capecitabine is an orally-administered chemotherapeutic agent used in The treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in The tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blo......
  • Global Oxaliplatin Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 104
    Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy The third stage colon cancer after resecting primary tumor completely. In this report, only The finished drug is covered, exclude API. The global Oxaliplatin market was valued at US$ 897.5 million in 2023 and is anticipated to reach US$ 1641.5 million by 2030, witnessing a CAGR of 8.9% duri......
  • Global Cancer Treatment Drugs Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 158
    According to our LPI (LP Information) latest study, the global Cancer Treatment Drugs market size was valued at US$ 174990 million in 2023. With growing demand in downstream market, the Cancer Treatment Drugs is forecast to a readjusted size of US$ 322540 million by 2030 with a CAGR of 9.1% during review period. The research report highlights the growth potential of the global Cancer Treatment Drugs market. Cancer Treatment Drugs are expected to show stable growth in the future market. H......
  • Global Capecitabine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93
    According to our LPI (LP Information) latest study, the global Capecitabine market size was valued at US$ 1003.9 million in 2023. With growing demand in downstream market, the Capecitabine is forecast to a readjusted size of US$ 975.1 million by 2030 with a CAGR of -0.4% during review period. The research report highlights the growth potential of the global Capecitabine market. Capecitabine are expected to show stable growth in the future market. However, product differentiation, reducin......
  • Global Methotrexate Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 95
    According to our LPI (LP Information) latest study, the global Methotrexate market size was valued at US$ 506 million in 2023. With growing demand in downstream market, the Methotrexate is forecast to a readjusted size of US$ 613.9 million by 2030 with a CAGR of 2.8% during review period. The research report highlights the growth potential of the global Methotrexate market. Methotrexate are expected to show stable growth in the future market. However, product differentiation, reducing co......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs